However, TfR-1 expressionmay be upregulated in benign proliferative disease as shown in MCF-10Acells; therefore, further refinement for tumor-targeting is necessary.Development of affibody-conjugated AFt delivery capsules that targetproteins overexpressed in certain mammary tumors remains a goal ofcurrent research, ultimately to enhance survival rates and improveprognoses in breast cancer patients. The gene discussed is TFRC; the disease is breast carcinoma.